News

Does Tirzepatide Cause Depression? The Evidence

Creator: Priya Raman, Health Writer
Published: 2026-09-25

Tirzepatide's own trials, FDA's 2026 class review and large health-record studies have not found that it causes depression or suicidal thoughts. A new low mood still deserves a prompt conversation with the prescriber.

Priya Raman, Health Writer September 25, 2026 7 min read

A ball of undyed wool yarn on plain linen, a close view

The short version

Current evidence does not show that tirzepatide causes depression: in a pooled analysis of 4,056 SURMOUNT participants, average depression scores were 1.9 on tirzepatide and 2.4 on placebo at week 72.
Suicidal thoughts were reported by 0.6% of people on tirzepatide and 0.6% on placebo in those trials, and FDA's January 2026 review of 91 GLP-1 trials with 107,910 patients found no increased risk.
FDA asked for the suicidal-thoughts warning to be removed; the current Zepbound label, revised August 2026, lists it as removed in February 2026.
The trials excluded people with a past suicide attempt or active major depression, so a psychiatric history still calls for individual review, including medicines such as lithium, now the subject of a European safety signal.
New or worsening low mood warrants a prompt call to the prescriber; suicidal thoughts need immediate help, and in the U.S. that means calling or texting 988.

Does tirzepatide cause depression? The best evidence so far says no, not as a general effect of the drug. In tirzepatide's own weight-loss trials, depression scores ended slightly lower on the drug than on placebo, and thoughts of suicide were reported by the same small share of people in both groups. In January 2026, FDA completed a review of the whole drug class, found no increased risk, and asked for the suicidal-thoughts warning to come off the Zepbound label.

That is not the same as "it never affects anyone's mood." If you are having thoughts of harming yourself, call or text 988 now, whatever you think the cause is.

Does tirzepatide cause depression? What changed on the label

Zepbound, the weight-management brand of tirzepatide, launched with a warning about suicidal behavior and ideation (thinking about or planning suicide). It did not come from tirzepatide data: FDA says similar language sits on other weight-loss medicines' labels, based on reports seen with older weight-loss drugs. The diabetes versions, Mounjaro included, did not carry it.

FDA began a closer look in July 2023 after reports of suicidal thoughts on GLP-1 medicines. Its Drug Safety Communication of January 13, 2026 pooled 91 placebo-controlled trials with 107,910 patients and found no increased risk of suicidal thoughts or behavior, depression, anxiety, irritability or psychosis. A claims study of 2,243,138 people with type 2 diabetes found no higher risk of intentional self-harm than with another diabetes drug class. FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the warning.

As of September 22, 2026, the day this article was written, the current Zepbound prescribing information ("Revised: 8/2026") lists "Suicidal Behavior and Ideation (Removed) 02/2026" among its recent major changes.

Two caveats. A label warning was never proof of harm, and removing it is not a promise that nobody will struggle. And FDA's review covered the whole class, with claims data from as far back as 2015, before tirzepatide was sold, so the tirzepatide-specific data below matter.

Tirzepatide and suicidal thoughts: what the trials measured

The most direct evidence is a 2026 analysis of three SURMOUNT trials (Wadden et al., Obesity), co-written by Lilly scientists. It pooled 4,056 adults with obesity or overweight on tirzepatide or placebo for 72 weeks, and it was post hoc: run after the trials ended rather than planned as their main question.

People filled in the PHQ-9 (a nine-question depression checklist scored from 0 to 27) and answered the C-SSRS (a structured set of questions about suicidal thoughts and actions) throughout.

Measure	Tirzepatide	Placebo
Average PHQ-9 at the start	2.7	2.6
Average PHQ-9 at week 72	1.9	2.4
Moved into a more severe depression category	18.2%	24.3%
Reported any suicidal thoughts	0.6% (17 of 2,793)	0.6% (7 of 1,246)
Suicidal behavior	2 people (0.1%)	none

A score near 2 means few or no symptoms, and most suicidal thoughts reported were judged low risk. Two cases of suicidal behavior is too few to say much either way; the authors called the rate similar to other drugs in the class.

The big limit: the trials screened out anyone with a past suicide attempt, and anyone with active or unstable major depression or another serious psychiatric illness, such as bipolar disorder, in the previous two years. The authors say the results cannot establish tirzepatide's psychiatric safety for people with major psychiatric illness.

What large real-world studies found

Health-record studies include people trials leave out. They are observational, comparing people who happened to get different medicines, so they show associations rather than cause.

Tirzepatide vs semaglutide. Across 85,546 matched pairs, a study published online July 8, 2026 found similar rates of new depression, anxiety or suicidal thoughts over two years (Chen et al., Diabetes, Obesity and Metabolism 2026).
Tirzepatide vs another weight-loss medicine. A U.S. study published June 29, 2026 found fewer new depression diagnoses over two years with tirzepatide than with naltrexone-bupropion. Among people without diabetes, tirzepatide was linked to slightly more new anxiety and insomnia diagnoses than semaglutide (Huang et al., Communications Medicine 2026).
Suicidal thoughts. Over about a year, 17 of 16,321 people on tirzepatide and 33 of 16,321 matched people on other weight-loss medicines had suicidal ideation or an attempt recorded (Yu et al., Frontiers in Psychiatry 2025).

Report databases, which count cases people chose to send in, can raise questions but not measure risk. A 2026 study of the World Health Organization's database found more reports of low mood and suicidal thoughts with GLP-1 medicines, tirzepatide included, than with other diabetes drugs, but no signal for suicide attempts or deaths. Those patients were 2.3 to 5 times more often already on antidepressants, which the authors read as existing vulnerability or reporting habits rather than a uniform drug effect (Aboukaoud et al., Journal of Affective Disorders 2026).

Tirzepatide mood changes: why someone might still feel low

Good averages do not rule out one person's experience, and a low stretch has other possible causes that can pile up in the same weeks:

Early tiredness while the dose is going up, which can feel like low mood (does tirzepatide make you tired?).
Nausea, eating far less than usual, and poorer sleep.
Losing food as a comfort. GLP-1 medicines act in brain areas that control appetite, one reason researchers keep studying mood.
Depression that was already there, which often travels with obesity and diabetes.

Timing alone cannot settle which it is; that is the prescriber's job. Tirzepatide side effects has the full list, and tirzepatide long-term side effects covers three years of data.

If you already take medicine for your mood

Because the trials excluded people with serious psychiatric illness, a depression history is something to review, not an automatic yes or no. A prescriber will ask about current symptoms, past self-harm, bipolar disorder, eating disorders and psychiatric medicines.

That last point matters. Tirzepatide slows stomach emptying, and the Zepbound label calls for monitoring of oral drugs with a narrow therapeutic index (a small gap between a working level and a harmful one). Lithium, used mainly for bipolar disorder, is one. In June 2026, the European Medicines Agency's safety committee opened a signal, an early question under investigation, about GLP-1 medicines raising lithium levels and asked lithium makers for a cumulative review (PRAC minutes of the June 8–11 meeting, dated August 31, 2026). A 2026 Mayo Clinic case report described lithium toxicity needing dialysis in someone with previously stable bipolar I disorder taking tirzepatide (Patarroyo-Rodriguez et al., Journal of Clinical Psychopharmacology 2026). A signal is not a confirmed interaction, but it is a reason to name lithium at intake.

Tirzepatide or semaglutide, if mood is the worry

In the studies above, the two main options look much alike on mood. That alone is no reason to choose one, but if sleep or anxiety becomes a sticking point on tirzepatide, semaglutide is an alternative a prescriber may weigh. Does semaglutide cause depression? walks through its record.

When a mood change needs attention

FDA's advice to patients is to tell a health care professional about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior. Persistent sadness, lost interest in things you enjoy or hopelessness is worth a call to your prescriber, who can weigh timing, dose changes and other medicines and decide whether treatment continues, pauses or changes.

Suicidal thoughts are urgent. In the U.S., call or text 988 for the Suicide & Crisis Lifeline, or call 911 if there is immediate danger. A reassuring average should never be used to explain away one person's crisis.

How the prescription route handles this

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The trials above tested tirzepatide made by its manufacturer, Lilly, rather than a compounded preparation. A licensed provider may still prescribe a compounded formulation when it is appropriate; that decision is between you and your doctor.

A licensed provider reviews every request, and not everyone qualifies. That review is where mood history, past self-harm and psychiatric medicines belong, and follow-up is where a new low stretch gets noticed.

Common questions

Does tirzepatide cause depression?

Current evidence does not show that it does. In a pooled analysis of three SURMOUNT trials with 4,056 adults, depression scores ended slightly lower on tirzepatide than on placebo, and FDA's January 2026 class review found no increased risk of depression or suicidal thoughts. Those trials excluded people with serious psychiatric illness, so a new mood change still deserves a prompt conversation with the prescriber.

Does Zepbound still carry a suicidal thoughts warning?

No. After FDA's review of January 13, 2026 found no increased risk of suicidal thoughts or behavior with GLP-1 medicines, it asked for the warning to be removed from Zepbound, Wegovy and Saxenda. The current Zepbound label, revised August 2026, lists the section as removed in February 2026. The diabetes versions, including Mounjaro, did not carry the warning.

Can tirzepatide change your mood?

Some people report feeling low or anxious while taking it, but timing alone cannot show the drug caused it. Early tiredness, nausea, eating much less, poor sleep and existing depression can all overlap in the same weeks. A 2026 health-record study linked tirzepatide to slightly more new anxiety and insomnia diagnoses than semaglutide in people without diabetes; it showed an association, not cause.

Can you take tirzepatide if you have depression?

A depression history does not answer the question by itself. A prescriber weighs how stable symptoms are, any past self-harm, bipolar disorder, eating disorders and current psychiatric medicines. That review matters because the SURMOUNT trials excluded people with a past suicide attempt or active major depression, and because some medicines, lithium among them, may need closer monitoring alongside tirzepatide.

Is tirzepatide worse than semaglutide for mood?

Not clearly. A 2026 study of 85,546 matched pairs found similar rates of new depression, anxiety or suicidal thoughts over two years. A second 2026 study found slightly more anxiety and insomnia diagnoses with tirzepatide among people without diabetes. Both were observational, so they show patterns rather than cause, and neither is a reason on its own to choose one drug over the other.

What should I do if I have suicidal thoughts on tirzepatide?

Get help right away, whatever you think the cause is. In the United States, call or text 988 for the Suicide & Crisis Lifeline, and call 911 or go to an emergency department if there is immediate danger. Then tell the prescribing clinician. A reassuring finding across thousands of trial patients should never be used to dismiss one person's crisis.